Update on Psychedelics: Science and Capital Markets
CPD for Lawyers: 1 Substantive Hour
![Nov 23 Update on Psychedelics Science and Capital Markets Website 876x254 Archive](/images/default-source/default-album/nov-23-update-on-psychedelics-science-and-capital-markets-website-876x254-archive.jpg?sfvrsn=215f5ed5_0)
ACCESS ARCHIVE
External Speakers:
Doug Drysdale, CEO - Cybin
Sumant S. Kulkarni, Managing Director - Canaccord Genuity LLC
David Wood, Chief Legal Officer & General Counsel - Psygen
The conversation surrounding psychedelic-assisted therapy as a mental health treatment has skyrocketed over the last year as we witnessed an explosion of new psychedelics companies. The industry is experiencing a rise in public and private financings, mergers and acquisitions and going-public transactions. Companies and academic institutions have formed mutually-beneficial partnerships to fund research, utilize data and protect intellectual property. |
For information regarding our webinars and communications, please contact:
Melanie Smilynov | rsvp@airdberlis.com | 416.863.1500 x2457
Should you experience any technical difficulties, we encourage you to review this help link to assist you in having an optimal webinar experience..